Search

Your search keyword '"Rao, Sheela"' showing total 389 results
Start Over Author "Rao, Sheela"
389 results on '"Rao, Sheela"'

2. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

Author

Lau, David K., Fong, Caroline, Arouri, Faten, Cortez, Lillian, Katifi, Hannah, Gonzalez-Exposito, Reyes, Razzaq, Muhammad Bilal, Li, Su, Macklin-Doherty, Aislinn, Hernandez, Monica Arenas, Hubank, Michael, Fribbens, Charlotte, Watkins, David, Rao, Sheela, Chau, Ian, Cunningham, David, and Starling, Naureen

Published
2023
Full Text
View/download PDF

4. Supplementary Figure S5 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

5. Supplementary Video S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

6. Supplementary Tables S1-S19 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

7. Supplementary Methods S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, primary, Cunningham, David, primary, Schirripa, Marta, primary, Lampis, Andrea, primary, Hahne, Jens C., primary, Tunariu, Nina, primary, Hong, Sung Pil, primary, Marchetti, Silvia, primary, Khan, Khurum, primary, Fontana, Elisa, primary, Angerilli, Valentina, primary, Delrieux, Mia, primary, Nava Rodrigues, Daniel, primary, Procaccio, Letizia, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Chau, Ian, primary, Braconi, Chiara, primary, Fotiadis, Nicos, primary, Begum, Ruwaida, primary, Guppy, Naomy, primary, Howell, Louise, primary, Valenti, Melanie, primary, Cribbes, Scott, primary, Kolozsvari, Bernadett, primary, Kirkin, Vladimir, primary, Lonardi, Sara, primary, Ghidini, Michele, primary, Passalacqua, Rodolfo, primary, Elghadi, Raghad, primary, Magnani, Luca, primary, Pinato, David J., primary, Di Maggio, Federica, primary, Ghelardi, Filippo, primary, Sottotetti, Elisa, primary, Vetere, Guglielmo, primary, Ciracì, Paolo, primary, Vlachogiannis, Georgios, primary, Pietrantonio, Filippo, primary, Cremolini, Chiara, primary, Cortellini, Alessio, primary, Loupakis, Fotios, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2024
Full Text
View/download PDF

8. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

Author

Hedayat, Somaieh, primary, Cascione, Luciano, additional, Cunningham, David, additional, Schirripa, Marta, additional, Lampis, Andrea, additional, Hahne, Jens C., additional, Tunariu, Nina, additional, Hong, Sung Pil, additional, Marchetti, Silvia, additional, Khan, Khurum, additional, Fontana, Elisa, additional, Angerilli, Valentina, additional, Delrieux, Mia, additional, Nava Rodrigues, Daniel, additional, Procaccio, Letizia, additional, Rao, Sheela, additional, Watkins, David, additional, Starling, Naureen, additional, Chau, Ian, additional, Braconi, Chiara, additional, Fotiadis, Nicos, additional, Begum, Ruwaida, additional, Guppy, Naomy, additional, Howell, Louise, additional, Valenti, Melanie, additional, Cribbes, Scott, additional, Kolozsvari, Bernadett, additional, Kirkin, Vladimir, additional, Lonardi, Sara, additional, Ghidini, Michele, additional, Passalacqua, Rodolfo, additional, Elghadi, Raghad, additional, Magnani, Luca, additional, Pinato, David J., additional, Di Maggio, Federica, additional, Ghelardi, Filippo, additional, Sottotetti, Elisa, additional, Vetere, Guglielmo, additional, Ciracì, Paolo, additional, Vlachogiannis, Georgios, additional, Pietrantonio, Filippo, additional, Cremolini, Chiara, additional, Cortellini, Alessio, additional, Loupakis, Fotios, additional, Fassan, Matteo, additional, and Valeri, Nicola, additional

Published
2024
Full Text
View/download PDF

12. Liquid biopsies for faster diagnosis of suspected advanced pancreatic and biliary tract cancers: ACCESS, a UK innovation programme.

Author

Jones, Lauren, primary, Mencel, Justin, additional, Mullen, Reed, additional, Sardo Infirri, Sofia, additional, MacDonald, Alan, additional, Fribbens, Charlotte Victoria, additional, Rao, Sheela, additional, Mahmood, Asif, additional, Galloway, Daniel, additional, Gupta, Sanjay, additional, Chadwick, Georgina, additional, Chau, Ian, additional, Ni, Melody, additional, McVeigh, Terri Patricia, additional, Popat, Sanjay, additional, Hubank, Michael, additional, Cunningham, David, additional, George, Angela Joy, additional, and Starling, Naureen, additional

Published
2024
Full Text
View/download PDF

13. Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.

Author

Lote, Hazel, primary, Giota, Eleftheria, additional, Fong, Caroline, additional, Gordon, Anderley, additional, Begum, Ruwaida, additional, Satchwell, Laura, additional, Kidd, Shannon, additional, Cromarty, Susan, additional, Fribbens, Charlotte Victoria, additional, Starling, Naureen, additional, Rao, Sheela, additional, Chau, Ian, additional, Cunningham, David, additional, and Zapata, Luis, additional

Published
2024
Full Text
View/download PDF

16. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage

Author

Carotenuto, Pietro, Amato, Francesco, Lampis, Andrea, Rae, Colin, Hedayat, Somaieh, Previdi, Maria C., Zito, Domenico, Raj, Maya, Guzzardo, Vincenza, Sclafani, Francesco, Lanese, Andrea, Parisi, Claudia, Vicentini, Caterina, Said-Huntingford, Ian, Hahne, Jens C., Hallsworth, Albert, Kirkin, Vladimir, Young, Kate, Begum, Ruwaida, Wotherspoon, Andrew, Kouvelakis, Kyriakos, Azevedo, Sergio Xavier, Michalarea, Vasiliki, Upstill-Goddard, Rosie, Rao, Sheela, Watkins, David, Starling, Naureen, Sadanandam, Anguraj, Chang, David K., Biankin, Andrew V., Jamieson, Nigel B., Scarpa, Aldo, Cunningham, David, Chau, Ian, Workman, Paul, Fassan, Matteo, Valeri, Nicola, and Braconi, Chiara

Published
2021
Full Text
View/download PDF

18. MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients

Author

Lote, Hazel, primary, Mousoullou, Florentia, additional, Vlachogiannis, George, additional, Lampis, Andrea, additional, Satchwell, Laura, additional, Peckitt, Clare, additional, Fong, Caroline, additional, Begum, Ruwaida, additional, Kidd, Shannon, additional, Cromarty, Susan, additional, Gordon, Anderley, additional, Fribbens, Charlotte, additional, Rao, Sheela, additional, Starling, Naureen, additional, Chau, Ian, additional, Cunningham, David, additional, and Valeri, Nicola, additional

Published
2023
Full Text
View/download PDF

19. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Author

Vlachogiannis, Georgios, Hedayat, Somaieh, Vatsiou, Alexandra, Jamin, Yann, Fernández-Mateos, Javier, Khan, Khurum, Lampis, Andrea, Eason, Katherine, Huntingford, Ian, Burke, Rosemary, Rata, Mihaela, Koh, Dow-Mu, Tunariu, Nina, Collins, David, Hulkki-Wilson, Sanna, Ragulan, Chanthirika, Spiteri, Inmaculada, Moorcraft, Sing Yu, Chau, Ian, Rao, Sheela, Watkins, David, Fotiadis, Nicos, Bali, Maria, Darvish-Damavandi, Mahnaz, Lote, Hazel, Eltahir, Zakaria, Smyth, Elizabeth C., Begum, Ruwaida, Clarke, Paul A., Hahne, Jens C., Dowsett, Mitchell, de Bono, Johann, Workman, Paul, Sadanandam, Anguraj, Fassan, Matteo, Sansom, Owen J., Eccles, Suzanne, Starling, Naureen, Braconi, Chiara, Sottoriva, Andrea, Robinson, Simon P., Cunningham, David, and Valeri, Nicola

Published
2018

22. Supplementary Table S4 from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial

Author

Khan, Khurum H., primary, Cunningham, David, primary, Werner, Benjamin, primary, Vlachogiannis, Georgios, primary, Spiteri, Inmaculada, primary, Heide, Timon, primary, Mateos, Javier Fernandez, primary, Vatsiou, Alexandra, primary, Lampis, Andrea, primary, Damavandi, Mahnaz Darvish, primary, Lote, Hazel, primary, Huntingford, Ian Said, primary, Hedayat, Somaieh, primary, Chau, Ian, primary, Tunariu, Nina, primary, Mentrasti, Giulia, primary, Trevisani, Francesco, primary, Rao, Sheela, primary, Anandappa, Gayathri, primary, Watkins, David, primary, Starling, Naureen, primary, Thomas, Janet, primary, Peckitt, Clare, primary, Khan, Nasir, primary, Rugge, Massimo, primary, Begum, Ruwaida, primary, Hezelova, Blanka, primary, Bryant, Annette, primary, Jones, Thomas, primary, Proszek, Paula, primary, Fassan, Matteo, primary, Hahne, Jens C., primary, Hubank, Michael, primary, Braconi, Chiara, primary, Sottoriva, Andrea, primary, and Valeri, Nicola, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Data from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial

Author

Khan, Khurum H., primary, Cunningham, David, primary, Werner, Benjamin, primary, Vlachogiannis, Georgios, primary, Spiteri, Inmaculada, primary, Heide, Timon, primary, Mateos, Javier Fernandez, primary, Vatsiou, Alexandra, primary, Lampis, Andrea, primary, Damavandi, Mahnaz Darvish, primary, Lote, Hazel, primary, Huntingford, Ian Said, primary, Hedayat, Somaieh, primary, Chau, Ian, primary, Tunariu, Nina, primary, Mentrasti, Giulia, primary, Trevisani, Francesco, primary, Rao, Sheela, primary, Anandappa, Gayathri, primary, Watkins, David, primary, Starling, Naureen, primary, Thomas, Janet, primary, Peckitt, Clare, primary, Khan, Nasir, primary, Rugge, Massimo, primary, Begum, Ruwaida, primary, Hezelova, Blanka, primary, Bryant, Annette, primary, Jones, Thomas, primary, Proszek, Paula, primary, Fassan, Matteo, primary, Hahne, Jens C., primary, Hubank, Michael, primary, Braconi, Chiara, primary, Sottoriva, Andrea, primary, and Valeri, Nicola, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Tables from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial

Author

Khan, Khurum H., primary, Cunningham, David, primary, Werner, Benjamin, primary, Vlachogiannis, Georgios, primary, Spiteri, Inmaculada, primary, Heide, Timon, primary, Mateos, Javier Fernandez, primary, Vatsiou, Alexandra, primary, Lampis, Andrea, primary, Damavandi, Mahnaz Darvish, primary, Lote, Hazel, primary, Huntingford, Ian Said, primary, Hedayat, Somaieh, primary, Chau, Ian, primary, Tunariu, Nina, primary, Mentrasti, Giulia, primary, Trevisani, Francesco, primary, Rao, Sheela, primary, Anandappa, Gayathri, primary, Watkins, David, primary, Starling, Naureen, primary, Thomas, Janet, primary, Peckitt, Clare, primary, Khan, Nasir, primary, Rugge, Massimo, primary, Begum, Ruwaida, primary, Hezelova, Blanka, primary, Bryant, Annette, primary, Jones, Thomas, primary, Proszek, Paula, primary, Fassan, Matteo, primary, Hahne, Jens C., primary, Hubank, Michael, primary, Braconi, Chiara, primary, Sottoriva, Andrea, primary, and Valeri, Nicola, primary

Published
2023
Full Text
View/download PDF

25. Data from Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial

Author

Khan, Khurum H., primary, Cunningham, David, primary, Werner, Benjamin, primary, Vlachogiannis, Georgios, primary, Spiteri, Inmaculada, primary, Heide, Timon, primary, Mateos, Javier Fernandez, primary, Vatsiou, Alexandra, primary, Lampis, Andrea, primary, Damavandi, Mahnaz Darvish, primary, Lote, Hazel, primary, Huntingford, Ian Said, primary, Hedayat, Somaieh, primary, Chau, Ian, primary, Tunariu, Nina, primary, Mentrasti, Giulia, primary, Trevisani, Francesco, primary, Rao, Sheela, primary, Anandappa, Gayathri, primary, Watkins, David, primary, Starling, Naureen, primary, Thomas, Janet, primary, Peckitt, Clare, primary, Khan, Nasir, primary, Rugge, Massimo, primary, Begum, Ruwaida, primary, Hezelova, Blanka, primary, Bryant, Annette, primary, Jones, Thomas, primary, Proszek, Paula, primary, Fassan, Matteo, primary, Hahne, Jens C., primary, Hubank, Michael, primary, Braconi, Chiara, primary, Sottoriva, Andrea, primary, and Valeri, Nicola, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Data from miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial

Author

Anandappa, Gayathri, primary, Lampis, Andrea, primary, Cunningham, David, primary, Khan, Khurum H., primary, Kouvelakis, Kyriakos, primary, Vlachogiannis, Georgios, primary, Hedayat, Somaieh, primary, Tunariu, Nina, primary, Rao, Sheela, primary, Watkins, David, primary, Starling, Naureen, primary, Braconi, Chiara, primary, Darvish-Damavandi, Mahnaz, primary, Lote, Hazel, primary, Thomas, Janet, primary, Peckitt, Clare, primary, Kalaitzaki, Ria, primary, Khan, Nasir, primary, Fotiadis, Nicos, primary, Rugge, Massimo, primary, Begum, Ruwaida, primary, Rana, Isma, primary, Bryant, Annette, primary, Hahne, Jens C., primary, Chau, Ian, primary, Fassan, Matteo, primary, and Valeri, Nicola, primary

Published
2023
Full Text
View/download PDF

27. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment

Author

Newey, Alice, Griffiths, Beatrice, Michaux, Justine, Pak, Hui Song, Stevenson, Brian J., Woolston, Andrew, Semiannikova, Maria, Spain, Georgia, Barber, Louise J., Matthews, Nik, Rao, Sheela, Watkins, David, Chau, Ian, Coukos, George, Racle, Julien, Gfeller, David, Starling, Naureen, Cunningham, David, Bassani-Sternberg, Michal, and Gerlinger, Marco

Published
2019
Full Text
View/download PDF

28. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

Author

Gonzalez-Exposito, Reyes, Semiannikova, Maria, Griffiths, Beatrice, Khan, Khurum, Barber, Louise J., Woolston, Andrew, Spain, Georgia, von Loga, Katharina, Challoner, Ben, Patel, Radhika, Ranes, Michael, Swain, Amanda, Thomas, Janet, Bryant, Annette, Saffery, Claire, Fotiadis, Nicos, Guettler, Sebastian, Mansfield, David, Melcher, Alan, Powles, Thomas, Rao, Sheela, Watkins, David, Chau, Ian, Matthews, Nik, Wallberg, Fredrik, Starling, Naureen, Cunningham, David, and Gerlinger, Marco

Published
2019
Full Text
View/download PDF

29. Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA).

Author

Gordon, Anderley, primary, Challoner, Benjamin, additional, Athauda, Avani, additional, Woolston, Andrew, additional, Mansukhani, Sonia, additional, Dunstan, Matt, additional, Petrou, Nikoletta, additional, Khabra, Komel, additional, Lazaro-Alcausi, Retchel, additional, Crux, Richard, additional, Borja, Victoria, additional, Begum, Ruwaida, additional, Rana, Isma, additional, Rao, Sheela, additional, Kumar, Sacheen, additional, Cunningham, David, additional, Chau, Ian, additional, Starling, Naureen, additional, Chaudry, M. Asif, additional, and Gerlinger, Marco, additional

Published
2023
Full Text
View/download PDF

30. Impact of infiltrating T cell subtypes on survival and response to FLOT chemotherapy in resectable oesophagogastric adenocarcinoma (OGA).

Author

Athauda, Avani, primary, Silveira, Tatiany, additional, Lund, Thomas, additional, von Loga, Katharina, additional, Challoner, Benjamin, additional, Rana, Isma, additional, Thomas, Janet, additional, Starling, Naureen, additional, Chau, Ian, additional, Rao, Sheela, additional, Watkins, David J., additional, Cunningham, David, additional, and Gerlinger, Marco, additional

Published
2023
Full Text
View/download PDF

31. MicroRNAs (miRs) as biomarkers of resistance to trastuzumab in HER2-positive oesophago-gastric cancer: Sub-study within the Planning Treatment for Oesophago-Gastric Cancer—A Randomised Maintenance Therapy Trial (PLATFORM).

Author

Lote, Hazel, primary, Mousoullou, Florentia, additional, Vlachogiannis, George, additional, Fong, Caroline, additional, Satchwell, Laura, additional, Peckitt, Clare, additional, Begum, Ruwaida, additional, Kidd, Shannon, additional, Cromarty, Susan, additional, Gordon, Anderley, additional, Fribbens, Charlotte Victoria, additional, Watkins, David J., additional, Rao, Sheela, additional, Chau, Ian, additional, Starling, Naureen, additional, Cunningham, David, additional, and Valeri, Nicola, additional

Published
2023
Full Text
View/download PDF

32. SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy

Author

Lau, David K, primary, Aresu, Maria, additional, Planche, Timothy, additional, Tran, Amina, additional, Lazaro-Alcausi, Retchel, additional, Duncan, Julie, additional, Kidd, Shannon, additional, Cromarty, Susan, additional, Begum, Ruwaida, additional, Rana, Isma, additional, Li, Su, additional, Mohamed, Ali Abdulnabi, additional, Monahan, Irene, additional, Clark, David J, additional, Eckersley, Nicholas, additional, Staines, Henry M, additional, Groppelli, Elisabetta, additional, Krishna, Sanjeev, additional, Mayora-Neto, Martin, additional, Temperton, Nigel, additional, Fribbens, Charlotte, additional, Watkins, David, additional, Starling, Naureen, additional, Chau, Ian, additional, Cunningham, David, additional, and Rao, Sheela, additional

Published
2022
Full Text
View/download PDF

36. Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study.

Author

Hodges, Nicola, Battersby, Nicholas, Rao, Sheela, Brown, Gina, the TRIGGER Study Group, Anandappa, Gayathri, Cunningham, David, Tait, Diana, Tekkis, Paris, Chong, Irene, Aitken, Katharine, Chau, Ian, Rasheed, Shahnawaz, Balyasnikova, Svetlana, Moran, Brendan, Falk, Stephen, Sizer, Bruce, Branagan, Graham, O'Toole, Lorcan, and Adusumalli, Madhavi

Abstract

Background: It is widely believed that small rectal tumors are more likely to have a good response to neoadjuvant treatment, which may influence the selection of patients for a 'watch and wait' strategy. Objective: The aim of this study was to investigate whether there is a relationship between baseline tumor length on magnetic resonance imaging (MRI) and response to chemoradiotherapy. Method: The 96 patients with locally advanced rectal cancer randomised (2:1–intervention:control) in the TRIGGER feasibility study where eligible. Baseline tumor length was defined as the maximal cranio-caudal length on baseline MRI (mm) and was recorded prospectively at study registration. Magnetic resonance tumor regression grade (mrTRG) assessment was performed on the post-chemoradiotherapy (CRT) MRI 4–6 weeks (no later than 10 weeks) post completion of CRT. This was routinely reported for patients in the intervention (mrTRG-directed management) arm and reported for the purposes of this study by the central radiologist in the control arm patients. Those with an mrTRG I/II response were defined as 'good responders' and those with an mrTRG III–V response were defined as 'poor responders'. Results: Overall, 94 patients had a post-CRT MRI performed and were included. Forty-three (46%) patients had a good response (mrTRG I/II) and 51 (54%) patients had a poor response (mrTRG III/IV). The median tumor length of good responders was 43 mm versus 50 mm (p < 0.001), with considerable overlap in tumor lengths between groups. Conclusion: Baseline tumor length on MRI is not a clinically useful biomarker to predict mrTRG tumor response to CRT and therefore patient suitability for a deferral of surgery trial. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy

Author

Lau, David K., Aresu, Maria, Planche, Timothy, Tran, Amina, Lazaro-Alcausi, Retchel, Duncan, Julie, Kidd, Shannon, Cromarty, Susan, Begum, Ruwaida, Rana, Isma, Li, Su, Mohamed, Ali Abdulnabi, Monahan, Irene, Clark, David J., Eckersley, Nicholas, Staines, Henry M., Groppelli, Elisabetta, Krishna, Sanjeev, Mayora-Neto, Martin, Temperton, Nigel J., Fribbens, Charlotte, Watkins, David, Starling, Naureen, Chau, Ian, Cunningham, David, Rao, Sheela, Lau, David K., Aresu, Maria, Planche, Timothy, Tran, Amina, Lazaro-Alcausi, Retchel, Duncan, Julie, Kidd, Shannon, Cromarty, Susan, Begum, Ruwaida, Rana, Isma, Li, Su, Mohamed, Ali Abdulnabi, Monahan, Irene, Clark, David J., Eckersley, Nicholas, Staines, Henry M., Groppelli, Elisabetta, Krishna, Sanjeev, Mayora-Neto, Martin, Temperton, Nigel J., Fribbens, Charlotte, Watkins, David, Starling, Naureen, Chau, Ian, Cunningham, David, and Rao, Sheela

Abstract

Introduction: Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer therapies is unclear. We conducted a prospective study to evaluate the prevalence of neutralizing antibodies in a cohort of GI cancer patients receiving chemotherapy following SARS-CoV-2 vaccination. Materials and methods: Between September 2020 and April 2021, patients with cancer undergoing chemotherapy were enrolled. At baseline (day 0), days 28, 56, and 84, we assessed serum antibodies to SARS-CoV-2 spike (anti-S) and anti-nucleocapsid (anti-NP) and concomitantly assessed virus neutralization using a pseudovirus neutralization assay. Patients received either the Pfizer/BioNTech BNT162b2, or the Oxford/AstraZeneca ChAdOx1 vaccine. Results: All 152 patients enrolled had a prior diagnosis of cancer; colorectal (n = 80, 52.6%), oesophagogastric (n = 38, 25.0%), and hepato pancreatic biliary (n = 22, 12.5%). Nearly all were receiving systemic anti-cancer therapy (99.3%). Of the 51 patients who did not receive a vaccination prior to, or during the study, 5 patients had detectable anti-NP antibodies. Ninety-nine patients received at least one dose of vaccine prior to, or during the study. Within 19 days following the first dose of vaccine, 30.0% had anti-S detected in serum which increased to 70.2% at days 20-39. In the 19 days following a second dose, anti-S positivity was 84.2% (32/38). However, pseudovirus neutralization titers (pVNT80) decreased from days 20 to 39. Conclusion: Despite the immunosuppressive effects of chemotherapy, 2 doses of SARS-CoV-2 vaccines are able to elicit a protective immune response in patients' ongoing treatment for gastrointestinal cancers. Decreases in pseudoviral neutralization were observed after 20-39 days, re-affirming the current recommendation for vaccine booster doses.

Published
2022

41. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)

Author

Rao, Sheela, Anandappa, Gayathri, Capdevila, Jaume, Dahan, Laëtitia, Evesque, Ludovic, Kim, Stefano, Saunders, Mark M.P., Gilbert, Duncan D.C., Jensen, Lars Henrik, Samalin, Emmanuelle, Spindler, Karen Lise Garm K.L., Tamberi, Stefano, Demols, Anne, Guren, Marianne M.G., Arnold, Dirk, Fakih, Marwan, Kayyal, T., Cornfeld, M., Tian, C., Catlett, M., Smith, M., Spano, Jean Philippe, Rao, Sheela, Anandappa, Gayathri, Capdevila, Jaume, Dahan, Laëtitia, Evesque, Ludovic, Kim, Stefano, Saunders, Mark M.P., Gilbert, Duncan D.C., Jensen, Lars Henrik, Samalin, Emmanuelle, Spindler, Karen Lise Garm K.L., Tamberi, Stefano, Demols, Anne, Guren, Marianne M.G., Arnold, Dirk, Fakih, Marwan, Kayyal, T., Cornfeld, M., Tian, C., Catlett, M., Smith, M., and Spano, Jean Philippe

Abstract

Background: Locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) has poor prognosis following platinum-based chemotherapy. Retifanlimab (INCMGA00012), a humanized monoclonal antibody targeting programmed death protein-1 (PD-1), demonstrated clinical activity across a range of solid tumors in clinical trials. We present results from POD1UM-202 (NCT03597295), an open-label, single-arm, multicenter, phase II study evaluating retifanlimab in patients with previously treated advanced or metastatic SCAC. Patients and methods: Patients ≥18 years of age had measurable disease and had progressed following, or were ineligible for, platinum-based therapy. Retifanlimab 500 mg was administered intravenously every 4 weeks. The primary endpoint was overall response rate (ORR) by independent central review. Secondary endpoints were duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: Overall, 94 patients were enrolled. At a median follow-up of 7.1 months (range, 0.9-19.4 months), ORR was 13.8% [95% confidence interval (CI) 7.6% to 22.5%], with one complete response (1.1%) and 12 partial responses (12.8%). Responses were observed regardless of human immunodeficiency virus or human papillomavirus status, programmed death ligand 1 (PD-L1) expression, or liver metastases. Stable disease was observed in 33 patients (35.1%) for a DCR of 48.9% (95% CI 38.5% to 59.5%). Median DOR was 9.5 months (range, 5.6 months-not estimable). Median (95% CI) PFS and OS were 2.3 (1.9-3.6) and 10.1 (7.9-not estimable) months, respectively. Retifanlimab safety in this population was consistent with previous experience for the PD-(L)1 inhibitor class. Conclusions: Retifanlimab demonstrated clinically meaningful and durable antitumor activity, and an acceptable safety profile in patients with previously treated locally advanced or metastatic SCAC who have progressed on or are intolerant to platinum-based che, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

43. A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer

Author

Franco, Pierfrancesco, primary, Segelov, Eva, additional, Johnsson, Anders, additional, Riechelmann, Rachel, additional, Guren, Marianne G., additional, Das, Prajnan, additional, Rao, Sheela, additional, Arnold, Dirk, additional, Spindler, Karen-Lise Garm, additional, Deutsch, Eric, additional, Krengli, Marco, additional, Tombolini, Vincenzo, additional, Sebag-Montefiore, David, additional, and De Felice, Francesca, additional

Published
2022
Full Text
View/download PDF

44. Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study

Author

Turkes, Fiona, primary, Bryant, Annette, additional, Begum, Ruwaida, additional, Davidson, Michael, additional, Kalaitzaki, Eleftheria, additional, Aresu, Maria, additional, Lazaro-Alcausi, Retchel, additional, Bryant, Jane, additional, Rana, Isma, additional, Chua, Sue, additional, Aronson, Lauren, additional, Hulkki-Wilson, Sanna, additional, Fribbens, Charlotte, additional, Watkins, David, additional, Rao, Sheela, additional, Starling, Naureen, additional, Cunningham, David, additional, Chong, Irene Y., additional, and Chau, Ian, additional

Published
2022
Full Text
View/download PDF

46. Investigating the prognostic value of TP53 and PIK3CA mutations in metastatic colorectal cancer (mCRC): Applying Structured Query Language (SQL) algorithms to real-world data from a high-volume U.K. tertiary cancer center.

Author

Fong, Caroline, primary, Mohamed, Ali Abdulnabi, additional, de Paula Neto, Geraldo Alves, additional, Teare, Marion, additional, Bourmpaki, Elli, additional, Peckitt, Clare, additional, Watkins, David J., additional, Rao, Sheela, additional, Starling, Naureen, additional, Chau, Ian, additional, and Cunningham, David, additional

Published
2022
Full Text
View/download PDF

47. Liquid biopsy for diagnosis in patients with suspected pancreatic and biliary tract cancers: PREVAIL ctDNA pilot trial.

Author

Mencel, Justin, primary, Feber, Andrew, additional, Begum, Ruwaida, additional, Carter, Paul, additional, Smalley, Michaela, additional, Bourmpaki, Elli, additional, Shur, Josh, additional, Zar, Sameer, additional, Kohoutova, Darina, additional, Popat, Sanjay, additional, George, Angela, additional, McVeigh, Terri Patricia, additional, Hubank, Michael, additional, Peckitt, Clare, additional, Fribbens, Charlotte Victoria, additional, Watkins, David J., additional, Rao, Sheela, additional, Chau, Ian, additional, Cunningham, David, additional, and Starling, Naureen, additional

Published
2022
Full Text
View/download PDF

49. Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma.

Author

Mencel, Justin and Rao, Sheela

Subjects
*IMMUNE checkpoint inhibitors, *SQUAMOUS cell carcinoma, *COMBINATION drug therapy, *IPILIMUMAB, *THERAPEUTICS, *HUMAN papillomavirus
Abstract

Metastatic squamous cell anal carcinoma (SCAC) accounts for almost 500 deaths per year in the UK. The optimal first-line treatment for metastatic SCAC consists of combination chemotherapy, which provides only modest benefit with a short duration of response. Currently, there is no established second-line treatment for chemorefractory disease. Retifanlimab (a programmed cell death protein 1 inhibitor) has shown promise in patients with refractory, metastatic SCAC based on the POD1UM-202 study, and has potential in the first-line setting in combination with chemotherapy. This article will review the current treatment paradigms for SCAC, including the future use of immune checkpoint inhibitors, with a focus on retifanlimab in the treatment of SCAC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results